Solasia Pharma KK (TSE:4597) Cyclically Adjusted Revenue per Share: 円5.63 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4597 Solasia Pharma KK TSE:4597
49 GF Score
Price 円28.00
GF Value 円2.41
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Solasia Pharma KK Cyclically Adjusted Revenue per Share?

Solasia Pharma KK TSE:4597 49 Cyclically Adjusted Revenue per Share is 円5.63 as of Mar. 2026. GuruFocus rates TSE:4597 with a GF Score™ of 49/100 and a GF Value™ of 円2.41 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Solasia Pharma KK's adjusted revenue per share for the three months ended in Mar. 2026 was 円0.022. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円5.63 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Solasia Pharma KK's average Cyclically Adjusted Revenue Growth Rate was 0.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-24), Solasia Pharma KK's current stock price is 円28.00. Solasia Pharma KK's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円5.63. Solasia Pharma KK's Cyclically Adjusted PS Ratio of today is 4.97.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Solasia Pharma KK was 8.23. The lowest was 4.09. And the median was 5.73.


Solasia Pharma KK  (TSE:4597) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Solasia Pharma KK's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=28.00/5.63
=4.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Solasia Pharma KK was 8.23. The lowest was 4.09. And the median was 5.73.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Solasia Pharma KK Cyclically Adjusted Revenue per Share Related Terms


Solasia Pharma KK Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Solasia Pharma KK's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solasia Pharma KK Cyclically Adjusted Revenue per Share Chart

Solasia Pharma KK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Solasia Pharma KK Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.58 5.47 0.00 0.00 5.63

TSE:4597 vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Solasia Pharma KK's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solasia Pharma KK Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Solasia Pharma KK's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Solasia Pharma KK's Cyclically Adjusted PS Ratio falls into.


TSE:4597
49GF Score
Solasia Pharma KK TSE:4597
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solasia Pharma KK Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Solasia Pharma KK's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.022/112.7000*112.7000
=0.022

Current CPI (Mar. 2026) = 112.7000.

Solasia Pharma KK Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 2.380 97.900 2.740
201606 0.016 98.100 0.018
201609 0.000 98.000 0.000
201612 3.569 98.400 4.088
201703 0.045 98.100 0.052
201706 0.023 98.500 0.026
201709 4.429 98.800 5.052
201712 0.011 99.400 0.012
201803 0.080 99.200 0.091
201806 0.862 99.200 0.979
201809 0.282 99.900 0.318
201812 1.984 99.700 2.243
201903 0.582 99.700 0.658
201906 0.657 99.800 0.742
201909 1.522 100.100 1.714
201912 9.635 100.500 10.805
202003 1.340 100.300 1.506
202006 0.721 99.900 0.813
202009 0.403 99.900 0.455
202012 1.390 99.300 1.578
202103 0.724 99.900 0.817
202106 1.430 99.500 1.620
202109 0.038 100.100 0.043
202112 2.067 100.100 2.327
202203 0.846 101.100 0.943
202206 0.527 101.800 0.583
202209 1.822 103.100 1.992
202212 3.612 104.100 3.910
202303 1.310 104.400 1.414
202306 1.839 105.200 1.970
202309 0.434 106.200 0.461
202312 0.089 106.800 0.094
202403 0.063 107.200 0.066
202406 0.314 108.200 0.327
202412 0.000 110.700 0.000
202503 0.115 111.100 0.117
202506 0.110 111.700 0.111
202509 0.000 112.000 0.000
202512 0.000 113.000 0.000
202603 0.022 112.700 0.022

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円5.63 mean?
Solasia Pharma KK (TSE:4597) has a Cyclically Adjusted Revenue per Share of 円5.63 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Solasia Pharma KK and its competitors.
Is Solasia Pharma KK's Cyclically Adjusted Revenue per Share too high?
Solasia Pharma KK's current Cyclically Adjusted Revenue per Share is 円5.63. Overall, Solasia Pharma KK has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Solasia Pharma KK's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Solasia Pharma KK's Cyclically Adjusted Revenue per Share of 円5.63 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Solasia Pharma KK and its competitors. Solasia Pharma KK's current Cyclically Adjusted Revenue per Share is 円5.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasia Pharma KK stock overvalued right now?
Based on GuruFocus' analysis, Solasia Pharma KK (TSE:4597) is currently considered Significantly Overvalued. The stock's GF Value™ is 円2.41, compared to a current price of 円28.00 — trading 1061.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円5.63. Solasia Pharma KK's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Solasia Pharma KK (TSE:4597), the current Cyclically Adjusted Revenue per Share is 円5.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Solasia Pharma KK (TSE:4597) Overvalued in 2026?

Based on GuruFocus' analysis, Solasia Pharma KK stock appears to be overvalued. The current stock price of 円28.00 is trading 1061.8% above its estimated GF Value™ of 円2.41. GuruFocus considers Solasia Pharma KK to be Significantly Overvalued.

Key valuation signals for TSE:4597:

  • Cyclically Adjusted Revenue per Share: 円5.63
  • GF Value™: 円2.41 vs. price of 円28.00 (1061.8% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the TSE:4597 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Solasia Pharma KK Business Description

Other Exchanges 9SO:Germany
Address 2-1-1 Shiba Park, 4th Floor, Sumitomo Real Estate Shiba Park Tower, Minato-ku, Tokyo, JPN, 105-0011
Solasia Pharma KK develops and distributes pharmaceuticals and medical devices relating to malignant tumors.
49GF Score

Get the complete analysis for TSE:4597

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円28.00
Price
円2.41
GF Value